DGK-alpha helps cancer cells gain traction and mobilize

January 23, 2012
A new study in the Journal of Cell Biology reveals how a lipid-converting enzyme helps cancer cells gain traction and mobilize. In this image, Rab-coupling protein (green) gathers at the tip of the pseudopod of an invasive tumor cell. Credit: Elena Rainero

Metastasizing cancer cells often express integrins that provide better traction. A new study in The Journal of Cell Biology reveals how a lipid-converting enzyme helps the cells mobilize these integrins.

Adhesive integrin proteins continually cycle to and from the cell surface. cells that carry mutant forms of the often bias the process, increasing the recycling of a particular integrin that offers a better grip on the fibronectin fibers found in tumors. To make this change, mutant p53 requires the Rab-coupling protein (RCP), which connects the integrins to the Rab GTPases that promote membrane recycling. In turn, RCP links up with a lipid called phosphatidic acid.

A team of researchers led by Jim Norman found that diacylglycerol kinase alpha (DGK-alpha), an enzyme that makes phosphatidic acid, helps cancer cells to get moving. Tumor cells that were short on DGK-alpha didn't recycle the integrin and didn't penetrate into slabs of extracellular matrix.

In metastasizing tumor cells, vesicles sporting RCP are tethered to the tips of the advancing pseudopods. Few of these vesicles built up if DGK-alpha was absent, however, indicating that vesicle tethering requires phosphatidic acid. The researchers found that the particular tumor cells they studied didn't boost levels of DGK-alpha in order to metastasize. Instead, the team thinks that DGK-alpha permits to move following the acquisition of . By manufacturing lipid that binds to RCP, DGK-alpha enables the tumor cells to tether vesicles containing the integrins close to the plasma membrane, where the integrins can readily recycle.

Explore further: New drug targets for squamous cell carcinoma

More information: Rainero, E., et al. 2012. J. Cell Biol. doi: 10.1083/jcb.201109112

Related Stories

New drug targets for squamous cell carcinoma

May 19, 2011
Researchers at Fred Hutchinson Cancer Research Center have discovered a new drug target for squamous cell carcinoma – the second most common form of skin cancer. Scientists in the laboratory of Valeri Vasioukhin, Ph.D., ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.